MedTrace Logo

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

NCT07475286 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-03-16

No results posted yet for this study

Summary

This trial will administer laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis from gastric cancer (GPC) who are receiving standard of care systemic chemotherapy.

Conditions

  • Synchronous Gastric Peritoneal Carcinomatosis
  • Gastroesophageal Peritoneal Carcinomatosis

Interventions

DRUG

Cisplatin

Cisplatin interferes with DNA replication, which kills the fastest proliferating cells.

DRUG

Mitomycin C

A drug that slows down the growth of cancer cells by making them less able to create the DNA, RNA, and proteins they need to multiply.

Sponsors & Collaborators

  • Dr. Samer AlMasri, MD

    collaborator UNKNOWN

  • Mohammad Haroon Asif Choudry

    lead OTHER

Principal Investigators

  • Haroon Choudry, MBBS, FACS · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2030-04-30
Completion
2034-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07475286 on ClinicalTrials.gov